MKI67 and adrenal cortex carcinoma: Moreover, the randomized ADIUVO trial reported no additional benefits of adjuvant mitotane in recurrence-free survival and OS among patients with stage I-III ACC, R0 surgery, and Ki-67 ≤10% compared with observation-alone group, which was similar to our finding that mitotane did not add survival benefits in stage I-III disease (26).